Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
June 15, 2009
- MEDICAL DEVICE NEWS IN BRIEF
June 15, 2009
- Tsumura: Record-High Profits Focusing on Kampo Medicines
June 15, 2009
- Takeda to Launch New Series of OTC Drugs for GI Disorders
June 15, 2009
- Industry Leaders Advocate Price Cut Exemption for Innovative Drugs at Chuikyo
June 15, 2009
- FPMAJ Proposes Replacement of Cost Calculation Method with a New One
June 15, 2009
- Opinions on the Review of the NHI Pricing Rule (Excerpt) Presented by the FPMAJ
June 15, 2009
- More Drugs Granted Premiums: Mr Nakagaki
June 15, 2009
- Sandoz's Somatropin to Be Approved as 1st Biosimilar Based on New Guidance
June 15, 2009
- Proposed Q&A for Guidance on Biosimilars Released
June 15, 2009
- MAA for Alogliptin in the EU to Be Delayed Until 2012: Takeda
June 15, 2009
- Asahi Kasei to Enhance Focus on Pharma Business
June 15, 2009
- NDA for Au AA21004 Also to Be Delayed: Takeda
June 15, 2009
- Meiji Aims at Pharma Sales of ¥145.0 Bil. in FY2011
June 15, 2009
- R&D NEWS IN BRIEF
June 15, 2009
- Meiji Licenses out ME3301 to Amalyte
June 15, 2009
- Vero Cell-derived Japanese Encephalitis Vaccine Released
June 15, 2009
- JCR Pharmaceuticals Expects Launching of EPO Biosimilar in April 2010
June 15, 2009
- OPINION／Why Empathy Is Key in Closing
June 15, 2009
- GSK, Pola to Copromote GSK's 4 Topical Agents
June 15, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…